0001104659-23-006545.txt : 20230125 0001104659-23-006545.hdr.sgml : 20230125 20230125161640 ACCESSION NUMBER: 0001104659-23-006545 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230120 FILED AS OF DATE: 20230125 DATE AS OF CHANGE: 20230125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bradley Greg CENTRAL INDEX KEY: 0001833504 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39752 FILM NUMBER: 23552660 MAIL ADDRESS: STREET 1: 200 U.S. 9 STREET 2: SUITE 500 CITY: MANALAPAN TOWNSHIP STATE: NJ ZIP: 07726 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Petros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001815903 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851410058 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 973-242-0005 MAIL ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS, 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 4 1 tm234334-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2023-01-20 0 0001815903 Petros Pharmaceuticals, Inc. PTPI 0001833504 Bradley Greg C/O PETROS PHARMACEUTICALS, INC. 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 1 0 0 0 Common Stock 2023-01-20 4 M 0 2264 A 2264 D Restricted Stock Units 2023-01-20 4 M 0 2264 0 D Common Stock 2264 0 D On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. On December 22, 2021, the reporting person was granted 2,264 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. /s/ Mitchell Arnold, attorney-in-fact 2023-01-25